ArticleInternational journal of pharmaceutics: X2026
Cutaneous delivery of bioactive components from a rice bran oil nanoemulsion and their biodistribution in porcine and human skin.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rice bran oil (RBO) is rich in antioxidants but the high lipophilicity and low concentration of key active components complicate its formulation for topical delivery. The objective of this study was to develop and to optimize an RBO-based nanoemulsion (RBO-NE) and to investigate the cutaneous delivery of three major bioactive components: 24-methylene cycloartanyl ferulate (24-MCF), γ-tocotrienol, and β-sitosterol. A validated UHPLC-MS/MS method with an internal standard was used to quantify the three molecules. The RBO-NE composition (10% RBO, 5% surfactant mix, 85% ultrapure water) was selected using a pseudo-ternary phase diagram, and ultrasonication was used to produce small globules (222 ± 2 nm, PDI 0.287), which were physically stable for three months at 4 °C. The cutaneous biodistribution of 24-MCF, γ-tocotrienol, and β-sitosterol (after consideration of endogenous β-sitosterol) was determined under infinite and finite dose conditions. Follicular targeting was evaluated by comparing delivery to pilosebaceous unit (PSU)-containing biopsies and control samples. Under infinite dose conditions, RBO-NE increased deposition of the three molecules compared to the control (RBO dispersed in hydroxypropyl-methylcellulose), with preferential accumulation in the epidermis. Delivery to the PSU from RBO-NE was approximately twice that to non-PSU containing skin samples; in contrast, the control showed no difference. Under finite dose conditions, deposition of 24-MCF and γ-tocotrienol in porcine skin was slightly superior to that in human skin. Cutaneous biodistribution studies demonstrated that (i) nanoemulsions could deliver highly lipophilic antioxidants from RBO to the epidermis and dermis, and (ii) the approach enabled simultaneous determination of the penetration profile of multiple RBO components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.